Download PDF
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2009; 03(03): 149-157
DOI: 10.1055/s-0037-1618671
Therapiekonzepte bei Adipositas
Schattauer GmbH

Adipositastherapie – facts and fiction!

Obesity therapy – facts and fiction!
F. Horber
1   Klinik Lindberg, Adipositaszentrum und Innere Medizin, Winterthur, Schweiz
,
R. Steffen
2   Klinik Beau Site, Bern, Schweiz
,
N. Potoczna
1   Klinik Lindberg, Adipositaszentrum und Innere Medizin, Winterthur, Schweiz
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Übergewicht und deren Folgeerkrankungen haben in den letzten Jahren auch in der Schweiz epidemische Ausmaße angenommen. Adipositas ist als eine multifaktorielle, neuroendokrine, chronische Erkrankung anerkannt worden. Als unabhängiger, modifizierbarer Risikofaktor für Diabetes mellitus Typ 2, Herzkreislauferkrankungen etc. sollte eine Therapie frühzeitig, effizient und vor allem langfristig, wahrscheinlich lebenslang, erfolgen. Zu den langfristigen konservativen, evidenzbasierten Therapiekonzepten gehört eine intensive Basistherapie, respektive eine Änderungen des Lifestyles bestehend aus: Reduktion der Gesamtkalorienzufuhr um mindestens 500 kcal unter dem individuellen Bedarf, Reduktion der Energiedichte der Mahlzeiten und Erhöhung der täglichen körperlichen Aktivität um mindestens 30 Minuten moderater Intensität. Nach Ausschöpfen der Basistherapie stehen als zusätzliche medikamentöse Unterstützung bisher zwei Medikamente zur Verfügung: Sibutramin und Orlistat.

Summary

Obesity is becoming epidemic also in Switzerland. Recently, obesity was recognized as a multifactorial, neuroendocrine, chronic illness. In addition, obesity is an independent and the only modifiable risk factor for co-morbidities e. g. diabetes mellitus type 2 or coronary heart disease. Therefore the therapy should be efficient and feasible on a longterm basis, probably lifelong. Evidence based long-term therapy or lifestyle changes consist of: Reduction of the total calorie intake of at least 500 kcal under the individual need, reduction of energy density of meals and increase of daily physical activity at least 30 minutes with moderate intensity. So far two drugs are recommended to support weight loss therapy: Sibutramine and Orlistat.

Schlüsselwörter

Adipositas - Sibutramin - Orlistat

Keywords

Obesity - sibutramine - orlistat
 

  • Literatur

  • 1 Obesity: preventing and managing the global epidemic: report of a WHO consultation. WHO Tech Rep Ser 1999; 894: 1-253.
    PubMedGoogle Scholar
  • 2 Finkelstein EA, Fiebelkorn IC, Wang G. HEALTH AFFAIRS. W3–219-W3–226.
    PubMedGoogle Scholar
  • 3 http://www.bag.admin.ch/verbrau/ernaehrung/d/Uebergewicht.htm .
    PubMed
  • 4 Bundesamt für Statistik, Schweizerische Gesundheitsbefragung 2001.
    PubMed
  • 5 Schneider H, Schmid A. Die Kosten der Adipositas in der Schweiz, Schlussbericht für Bundesamt für Gesundheit (BAG). 29.04.2004.
    PubMedGoogle Scholar
  • 6 Bray GA. Obesity is a chronic, relapsing neurochemical disease. International Journal of Obesity 2004; 28: 34-38.
    CrossrefPubMedGoogle Scholar
  • 7 Rosenbaum M, Leibel L, Hirsch J. Obesity. N Engl J Med 1997; 06: 396-407.
    PubMedGoogle Scholar
  • 8 Art. 32 Abs 1,2 und 3; Art. 33KVV sowie Krankenpflege-Leistungsverordnung (KLV)
    PubMed
  • 9 CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycaemic control, intensified hypertension control, and serum cholesterol level reduction in Type 2 diabetes. JAMA 2002; 287: 2542-2551.
    CrossrefPubMedGoogle Scholar
  • 10 Ballantyne CM. Emerging CHD risk factors and new approaches to risk management. http://www.lipidsonline.org/slides .
    PubMedGoogle Scholar
  • 11 Clegg A, Colquitt J, Sidhu M. et al. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes 2003; 27: 1167-1177.
    CrossrefPubMedGoogle Scholar
  • 12 Consensus über die Behandlung der Adipositas in der Schweiz 1999. Golay A für die Consensusgruppe; Horber FF für die Bariatrische Chirurgie. Schweiz Med Wochenschr 1999; 49 (Suppl. 114) 3S-20S.
    PubMedGoogle Scholar
  • 13 The Evidence Report, NIH PUBLICATION, NO. 98–4083, SEPTEMBER 1998,. NATIONAL INSTITUTES OF HEALTH
    PubMed
  • 14 Guideline für, Guideline Schweiz. Ärztezeitung 1999; 80: 581-584.
    PubMedGoogle Scholar
  • 15 Tataranni TP. Mechanisms of weight gain in humans. Editorial. Eur Rev Med Pharmacol Sci 2000; 04: 1-7.
    PubMedGoogle Scholar
  • 16 Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight.loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579-584.
    CrossrefPubMedGoogle Scholar
  • 17 Hauner H, Hamann A, Husemann B. et al. Evidenzbasierte Leitlinie – Adipositas: Prävention und Therapie der Adipositas. Deutsche Adipositas-Gesellschaft. Deutsche Diabetes-Gesellschaft, Deutsche Gesellschaft für Ernährung, 12/2000. http://www.adipositas-gesellschaft.de/Leitlinien/Evidenzbasierte-Leitlinien-Adipositas.pdf .
    PubMedGoogle Scholar
  • 18 Samaha FF, Iqba N, Seshadri P. et al. A Low-Carbohydrate diet as Compared with a Low-Fat Diet in Severe Obesity. N Engl J Med 2003; 348: 2074-2081.
    CrossrefPubMedGoogle Scholar
  • 19 Stern L, Iqbal N, Seshadri P. et al. The effects of lowcarbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004; 140: 778-785.
    CrossrefPubMedGoogle Scholar
  • 20 Frost G, Leeds A, Trew G. et al. Insulin sensitivity in women at risk of coronary heart disease and the effect of a low glycaemic index diet. Metabolism 1998; 47: 1245-1251.
    CrossrefPubMedGoogle Scholar
  • 21 Frost GS, Brynes AE, Bovill-Taylor C, Dornhorst A. A prospective randomised trial to determine the efficacy of a low glycaemic index diet given in addition to healthy eating and weight loss advice in patients with coronary heart disease European Journal of Clinical Nutrition. 2004; 58: 121-127.
    PubMedGoogle Scholar
  • 22 Prentice AM, Jebb SA. Fast food, energy density and obesity: a possible mechanistic link. Obes Rev 2003; 04: 187-194.
    CrossrefPubMedGoogle Scholar
  • 23 Rolls B, Barnet R. Volumentrics, ISBN 0–06–0983272–4.
    PubMed
  • 24 Stunkard AJ, Allison CA. Two forms of disordered eating in obesity: binge eating and night eating. International Journal of Obesity 2003; 27: 1-12.
    CrossrefPubMedGoogle Scholar
  • 25 US Departement of Health and Human Services. Physical activity and health: A report of the Surgeon General. US Departement of Health and Human Services; Atlanta, GA: 1996
    Google Scholar
  • 26 Martijn B, Katan PhD. Weight-loss diets for the prevention and treatment of obesity. New Engl J Med. 360/9/923-925.
    PubMedGoogle Scholar
  • 27 Shai I. et al. Weight loss with low-carbohydrate, mediterranean or low-fat diet. New Engl J Med 2008; 359: 229-241.
    CrossrefPubMedGoogle Scholar
  • 28 Frank M. Comparison of weight-loss diets with different compositions of fat, protein and carbohydrates. New Engl J Med 2009; 360: 859-873.
    CrossrefPubMedGoogle Scholar
  • 29 Saris WH, Blair SN, van Baak MA. et al. How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conferenvce and consensus statement. Obesity Reviews 2003; 04: 101-114.
    CrossrefPubMedGoogle Scholar
  • 30 Tuomilehto J, Lindström J, Eriksson JG. et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344 (18) 1343-1350.
    CrossrefPubMedGoogle Scholar
  • 31 Westerterp-Plantenga MS, van Marken WDLichtenbelt, Cilissen C, Top S. Energy metabolism in women during short exposure to the thermoneutral zone. Physiol Behav 2002; 75: 227-235.
    CrossrefPubMedGoogle Scholar
  • 32 EHCS 2000. Housing Research Summary: English House Condition Survey 1996: Energy Report (No. 120). Office of the Deputy PrimeMinister, The Stationary Office; UK.:
    Google Scholar
  • 33 Race and Hispanic origin 1790–1990. Available at: http://www.census.gov/population/documentation/twps0056/tab01.pdf (accessed March 15, 2005).
    PubMed
  • 34 von Kries R, Toschke AM, Wurmser H. et al. Reduced risk for overweight and obesity in 5and 6-years-old children by duration of sleep – a crosssectional study. Int J Obes Relat Metab Disord 2002; 26: 710-716.
    CrossrefPubMedGoogle Scholar
  • 35 Gangwisch JE, Malaspina D, Boden-Albala B, Heymsfield SB. Inadequate sleep as a risk factor for obesity: analysis of the NHANES I. Sleep 2005; 28: 1289-1296.
    CrossrefPubMedGoogle Scholar
  • 36 Everson CA. Functional consequences of sustained sleep deprivation in the rat. Behav Brain Res 1995; 69: 43-54.
    CrossrefPubMedGoogle Scholar
  • 37 Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999; 354: 1435-1439.
    CrossrefPubMedGoogle Scholar
  • 38 Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141: 846-850.
    CrossrefPubMedGoogle Scholar
  • 39 Bonnet MH, Arand DL. We are chronically sleep deprived. Sleep 1995; 18: 908-911.
    CrossrefPubMedGoogle Scholar
  • 40 Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to adolescence: reference values and generational trends. Pediatrics 2003; 111: 302-307.
    CrossrefPubMedGoogle Scholar
  • 41 Resta O, Foschino BMP, Bonfitto P. et al. Low sleep quality and daytime sleepiness in obese patients without obstructive sleep apnoea syndrome. J Intern Med 2003; 253: 536-543.
    CrossrefPubMedGoogle Scholar
  • 42 Jessen AB, Buemann B, Toubro S. et al. The appetitesuppressant effect of nicotine is enhanced by caffeine. Diab Obes Metab 2005; 07: 327-333.
    CrossrefPubMedGoogle Scholar
  • 43 Flegal KM, Troiano RP, Pamuk ER. et al. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995; 333: 1165-1170.
    CrossrefPubMedGoogle Scholar
  • 44 Segal NL, Allison DB. Twins and virtual twins: bases of relative body weight revisited. Int J Obes Relat Metab Disord 2002; 26: 437-441.
    CrossrefPubMedGoogle Scholar
  • 45 Weng HH, Bastion LA, Taylor DH. et al. Number of children associated with obesity in middle-aged women and men: results from the health and retirement study. J Womens Health 2004; 13: 85-91.
    CrossrefPubMedGoogle Scholar
  • 46 Kral JG, Biron S, Simard S. et al. Large Maternal Weight Loss From Obesity Surgery Prevents Transmission of Obesity to Children Who Were Followed for 2 to 18 Years. Pediatrics 2006; 118: 1644-1649.
    CrossrefPubMedGoogle Scholar
  • 47 Pelletier C, Imbeault P, Tremblay A. Energy balance and pollution by organochlorines and polychlorinated biphenyls. Obes Rev 2003; 04: 17-24.
    CrossrefPubMedGoogle Scholar
  • 48 Noren K, Meironyte D. Certain organochlorine and organobromine contaminants in Swedish human milk in perspective of past 20–30 years. Chemosphere 2000; 40: 1111-1123.
    CrossrefPubMedGoogle Scholar
  • 49 SwissBalance, die Ernährungsbewegung vom Bundesamt für Gesundheit und von Gesundheitsförderung Schweiz. 2002 www.saps.ch .
    PubMedGoogle Scholar
  • 50 Heal DJ, Aspley S, Prow MR. et al. Sibutramine: a novel antiobesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J obes Relat Metab Disord 1998; 22 (Suppl. 01) S18-S28.
    PubMedGoogle Scholar
  • 51 Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 06: 1-11.
    CrossrefPubMedGoogle Scholar
  • 52 Astrup A, Lundsgaard C, Stock MJ. Is obesity contagious?. Int J Obes 1998; 22: S30-S35.
    PubMedGoogle Scholar
  • 53 Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23: 1016-1024.
    CrossrefPubMedGoogle Scholar
  • 54 Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999; 23: 1009-1015.
    CrossrefPubMedGoogle Scholar
  • 55 Hansen DL, Toubro S, Stock MJ. et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-1186.
    CrossrefPubMedGoogle Scholar
  • 56 Appolinario JC, Bacaltchuk J, Sichieri R. et al. A randomized, double blind placebo controlled study of sibutramine in the treatment of Binge-eating disorder. Arch Gen Psychiatry 2003; 60: 1109-1116.
    CrossrefPubMedGoogle Scholar
  • 57 Astrup A, Toubro S. When, for whom and how use sibutramine, Int J Obesity. 2001; (Suppl. 04) S2-S7.
    PubMedGoogle Scholar
  • 58 Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2004
    Google Scholar
  • 59 Gokcel A, Karakose H, Ertorer EM. et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957-1960.
    CrossrefPubMedGoogle Scholar
  • 60 Arzneimittel-Kompendium der Schweiz.
    PubMed
  • 61 BASF Pharma/Knoll. Cost–utility analysis of msibutramine. Submission to NICE. Nottingham: Knoll Limited; 2000
    Google Scholar
  • 62 O’Meara S, Riemsma R, Shirran L. et al. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment Health Technology Assessment. 2002 06. 06
    PubMedGoogle Scholar
  • 63 Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004; 24 (01) 9-19.
    CrossrefPubMedGoogle Scholar
  • 64 Hollander PA, Elbein SC, Hirsch IB. et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomised double-blind study. Diabetes Care 1998; 21: 1288-1294.
    CrossrefPubMedGoogle Scholar
  • 65 Kelley DE, Bray GA, Pi-Sunyer FX. et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-1041.
    CrossrefPubMedGoogle Scholar
  • 66 Kelley DE, Bray GA, Pi-Sunyer FX. et al. Effects of weight loss with Orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-1326.
    CrossrefPubMedGoogle Scholar
  • 67 Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
    CrossrefPubMedGoogle Scholar
  • 68 Ruof J, Golay A, Berne C. et al. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes Relat Metab Disord 2005; 29 (05) 517-523.
    CrossrefPubMedGoogle Scholar
  • 69 Fattore L, Spano MS, Deiana S. et al. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 2007; 53 (01) 1-16 Epub 2006 Jul 12.
    CrossrefPubMedGoogle Scholar
  • 70 Abenhaim L, Moride Y, Brenot F. et al. Appetite-suppressant drugs and the risk of pulmonary hypertension. NEJM 1996; 335: 609-616.
    CrossrefPubMedGoogle Scholar
  • 71 Mark EJ, Patalas ED, Chang HT. et al. Fatal pulmonary hypertension with short-term use of fenfluramine and phentermine. NEJM 1997; 337: 602-606.
    CrossrefPubMedGoogle Scholar
  • 72 Vivero LE, Anderson PO, Clark RF. A close loook at fenfluramnie and dexfenfluramine. J Emerg Med 1998; 16: 197-205.
    CrossrefPubMedGoogle Scholar
  • 73 Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocrinol Rev 1999; 20: 805-875.
    CrossrefPubMedGoogle Scholar
  • 74 Kernan WN, Viscoli CM, Brass LM. et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343 (25) 1826-1832.
    CrossrefPubMedGoogle Scholar
  • 75 Endgültiges Gutachten des Ausschusses für Arzneimittelspezialitäten gemäss Artikel 12 der geänderten Richtlinie 75/319/EWG. Typ I 1, CPMP/ 101–109/96, www.eudra.org .
    PubMedGoogle Scholar
  • 76 Endgültiges Gutachten des Ausschusses für Arzneispezialitäten gemäss Artikel 12 der geänderten Richtlinie 75/319/EWG CPMP/111–112/96. www.eudra.org .
    PubMedGoogle Scholar
  • 77 Endgültiges Gutachten des Ausschusses für Arzneimittelspezialitäten gemäss, Artikel 12 der geänderten Richtlinie 75/319/EWG. Typ III 1. www.eudra.org .
    PubMedGoogle Scholar
  • 78 http://www.dg-kassenarztrecht.de/RID/2003/RID_index01_03.htm .
    PubMed
  • 79 Marktanteilsberechnung in Anzahl Behandlungsmonaten, basierend auf: Pharma Panel Daten Juni 2004/IHA-IMS Health GmbH, Hergiswil.
    PubMed
  • 80 Friedmann JM. A War on Obesity, not the Obese. Science 2003; 2999: 856-858.
    PubMedGoogle Scholar